Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,611.70 | 38.30 | 0.45% |
CAC 40 | 7,910.49 | 0.00 | 0.00% |
DAX 40 | 24,122.40 | 86.29 | 0.36% |
Dow JONES (US) | 41,908.87 | 768.37 | -1.80% |
FTSE 100 | 8,786.46 | 5.34 | 0.06% |
HKSE | 23,827.78 | 146.30 | 0.62% |
NASDAQ | 18,907.20 | 235.52 | -1.23% |
Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
S&P 500 | 5,855.15 | 85.31 | -1.44% |
S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
SSE Composite Index | 3,387.57 | 7.10 | 0.21% |